Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 2/2017

01-04-2017

Applying Subtractive Hybridization Technique to Enrich and Amplify Tumor-Specific Transcripts of Esophageal Squamous Cell Carcinoma

Authors: Reihaneh Alsadat Mahmoudian, Mohammad Reza Abbaszadegan, Mehran Gholamin

Published in: Pathology & Oncology Research | Issue 2/2017

Login to get access

Abstract

Subtractive hybridization (SH) as an efficient and powerful approach can be applied to isolate differentially expressed transcripts as well as detect of involved mRNAs in various cellular processes, particularly diseases and malignancies. This procedure leads to the enrichment of specific low copy transcripts of tumor cells. Having developed a new approach for SH to isolate tumor specific transcripts, we facilitated discovery of uniquely expressed genes in esophageal squamous cell carcinoma (ESCC). Total RNA was extracted from the fresh tumoral and their adjacent normal tissues, and purified using the Switch Mechanism At the 5ʹ end of Reverse Transcript (SMART) method. Following cDNA synthesis of normal mRNAs using magnetic beads, it was hybridized with tumor mRNAs. To enhance efficiency of subtraction, hybridization was repeated three rounds. Finally, amplification of subtracted tumor-specific transcripts was carried out using in vitro transcription. The subtracted tumoral mRNAs was analyzed quantitatively using real-time PCR for both tumor-specific and housekeeping genes. The subtracted mRNA was confirmed as tumor-specific mRNA pool using RT-PCR and quantitative real-time PCR assessment. The elevated level of tumor-specific transcripts such as MAGE-A4 and CD44 as well as declined copy number of housekeeping genes such as GAPDH, β actin and β2-microglobulin, were confirmed in subtracted tumoral mRNA. The presence of tumor genes was confirmed after the SH procedure. The designed SH method in combination with SMART technique can isolate and amplify high quality tumor-specific transcripts even from small amount of tumor tissues. Removal of common transcripts from the extracted tumoral mRNAs using SH, leads to the enrichment of tumor-specific transcripts. The isolated transcripts are of interest because of their probable roles in ESCC progression and development. In addition, these tumor-specific mRNAs can be applied for future vaccine cancer studies.
Literature
1.
Moghbeli M, Moghbeli F, Forghanifard MM, Garayali A, Abbaszadegan MR (2013) Cancer stem cell markers in esophageal cancer. Am J Cancer Sci 2(1):37–50
2.
Taleb S, Abbaszadegan MR, Moghbeli M, Roudbari NH, Forghanifard MM (2014) HES1 as an independent prognostic marker in esophageal squamous cell carcinoma. J Gastrointest Cancer 45(4):466–471CrossRefPubMed
3.
Gholamin M, Moaven O, Memar B, Farshchian M, Naseh H, Malekzadeh R, et al. (2009) Overexpression and interactions of interleukin-10, transforming growth factor, and vascular endothelial growth factor in esophageal squamous cell carcinoma. World J Surg 33(7):1439–1445CrossRefPubMed
4.
Gholamin M, Moaven O, Farshchian M, Mahmoudi M, Sankian M, Memar B, et al. (2010) Induction of cytotoxic T lymphocytes primed with tumor RNA-loaded dendritic cells in esophageal squamous cell carcinoma: preliminary step for DC vaccine design. BMC Cancer 10(1):261CrossRefPubMedPubMedCentral
5.
Kahkhaie KR, Moaven O, Abbaszadegan MR, Montazer M, Gholamin M (2014) Specific MUC1 splice variants are correlated with tumor progression in esophageal cancer. World J Surg 38(8):2052–2057CrossRefPubMed
6.
Napier KJ, Scheerer M, Misra S (2014) Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol 6(5):112CrossRefPubMedPubMedCentral
7.
Kurtz DM, Gambhir SS (2014) Tracking cellular and immune therapies in cancer. Emerging Applications of Molecular Imaging to Oncology, 124:257-296
8.
Forghanifard MM, Gholamin M, Farshchian M, Moaven O, Memar B, Forghani MN, et al. (2011) Cancer-testis gene expression profiling in esophageal squamous cell carcinoma: identification of specific tumor marker and potential targets for immunotherapy. Cancer Biol Ther 12(3):191–197CrossRefPubMed
9.
Bringmann A, Held SAE, Heine A, Brossart P (2010) RNA vaccines in cancer treatment. BioMed Res Int 2010
10.
11.
12.
Forghanifard MM, Amani J, Gheybi E, Abbaszadegan MR (2012) In silico analysis of chimeric polytope of cancer/testis antigens for dendritic cell-based immune-gene therapy applications. Gene Ther Mol Biol 14:87–96
13.
Silva JM, Videira M, Gaspar R, Préat V, Florindo HF (2013) Immune system targeting by biodegradable nanoparticles for cancer vaccines. J Control Release 168(2):179–199CrossRefPubMed
14.
Matera L (2010) The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer. Cancer Treat Rev 36(2):131–141CrossRefPubMed
15.
Cronwright G, Le Blanc K, Gotherstrom C, Darcy P, Ehnman M, Brodin B (2005) Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res 65(6):2207–2215CrossRefPubMed
16.
Gholamin M, Moaven O, Farshchian M, Rajabi-Mashhadi MT, Mahmoudi M, Sankian M, et al. (2010) Highly efficient transfection of dendritic cells derived from esophageal squamous cell carcinoma patient: optimization with green fluorescent protein and validation with tumor RNA as a tool for immuno-genetherapy. Iran J Biotechnol 8(2):121–126
17.
Garg NK, Dwivedi P, Prabha P, Tyagi RK (2013) RNA pulsed dendritic cells: an approach for cancer immunotherapy. Vaccine 31(8):1141–1156CrossRefPubMed
18.
Sagerstrm CG, Sun BI, Sive HL (1997) Subtractive cloning: past, present, and future. Annu Rev Biochem 66(1):751–783CrossRef
19.
Wu N, Matand K, Williams S (2009) A novel mRNA level subtraction method for quick identification of target-orientated uniquely expressed genes between peanut immature pod and leaf. Biological Procedures Online 12(1):44–55CrossRefPubMedPubMedCentral
20.
21.
Lin T-Y, Ying, S-Y (2003) Subtractive hybridization for the identification of differentially expressed genes using uraci-DNA glycosylase and mung-bean nuclease. Generation of cDNA Libraries. Springer, p 239-251
22.
Wang Z, Jones, MGK (2003) cDNA generation on paramagnetic beads. Generation of cDNA Libraries. Springer, p 25-31
23.
Barooei R, Mahmoudian RA, Abbaszadegan MR, Mansouri A, Gholamin M (2015) Evaluation of thymic stromal lymphopoietin (TSLP) and its correlation with lymphatic metastasis in human gastric cancer. Med Oncol 32(8):1–8CrossRef
24.
Moghbeli M, Forghanifard MM, Aarabi A, Mansourian A, Abbaszadegan MR (2014) Clinicopathological sex-related relevance of Musashi1 mRNA expression in esophageal squamous cell carcinoma patients. Pathol Oncol Res 20(2):427–433CrossRefPubMed
25.
Alsadat Mahmoudian R, Abbaszadegan MR, Mansouri A, Gholamin M (2015) Amplification of Tumor Transcripts from Limited Quantity of Esophageal Squamous Cell Carcinoma Tissue Samples. Am J Cancer Sci 4(1):54–62
26.
Mansouri A, Foroughmand AM, Abbaszadegan MR, Memar B, Mahmoudian RA, Gholamin M (2015) Expression analysis of CD44 isoforms S and V3, in patients with esophageal squamous cell carcinoma. Iran J Basic Med Sci 18(4):380PubMedPubMedCentral
27.
Forghanifard MM, Gholamin M, Moaven O, Farshchian M, Ghahraman M, Aledavood A, et al. (2014) Neoantigen in esophageal squamous cell carcinoma for dendritic cell-based cancer vaccine development. Med Oncol 31(10):1–7CrossRef
28.
Nair SK, Morse M, Boczkowski D, Cumming RI, Vasovic L, Gilboa E, et al. (2002) Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 235(4):540CrossRefPubMedPubMedCentral
29.
Hossein Naseh M, Bahram Memar M, Bagheri R, MontazerMD M, AbbaszadeganPhD MR (2013) A Cancer-array approach elucidates the immune escape mechanism and defects in the DNA repair system in esophageal squamous cell carcinoma. Arch Iran Med 16(8):463PubMed
30.
Amatschek S, Koenig U, Auer H, Steinlein P, Pacher M, Gruenfelder A, et al. (2004) Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res 64(3):844–856CrossRefPubMed
31.
Even-Desrumeaux K, Baty D, Chames P (2011) State of the art in tumor antigen and biomarker discovery. Cancer 3(2):2554–2596CrossRef
32.
33.
Heiser A, Dahm P, Yancey DR, Maurice MA, Boczkowski D, Nair SK, et al. (2000) Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 164(10):5508–5514CrossRefPubMed
34.
Müller MR, Grünebach F, Nencioni A, Brossart P (2003) Transfection of dendritic cells with RNA induces CD4-and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes. J Immunol 170(12):5892–5896CrossRefPubMed
35.
Gilboa E, Vieweg J (2004) Cancer immunotherapy with mRNA transfected dendritic cells. Immunol Rev 199(1):251–263CrossRefPubMed
36.
37.
Yang F, Yang X-F (2005) New concepts in tumor antigens: their significance in future immunotherapies for tumors. Cell Mol Immunol 2(5):331–341PubMed
38.
Ghafouri-Fard S, Modarressi M-H (2009) Cancer-testis antigens: potential targets for cancer immunotherapy. Arch Iran Med 12(4):395–404PubMed
39.
Amos SM, Duong CPM, Westwood JA, Ritchie DS, Junghans RP, Darcy PK, et al. (2011) Autoimmunity associated with immunotherapy of cancer. Blood 118(3):499–509CrossRefPubMed
40.
Kaufman HL, Wolchok JD (2006) Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapy. J Clin Oncol 24(15):2230–2232CrossRefPubMed
41.
Blumberg B, Belmonte, JCI. (1999) Subtractive hybridization and construction of cDNA libraries. Molecular Embryology. Springer, p 555–574.
42.
Mishra RN, Ramesha A, Kaul T, Nair S, Sopory SK, Reddy MK (2005) A modified cDNA subtraction to identify differentially expressed genes from plants with universal application to other eukaryotes. Anal Biochem 345(1):149–157CrossRefPubMed
43.
D’Urso OF, D’Urso PI, Storelli C, Marsigliante S (2009) Solid phase subtractive cloning in differentially expressed genes identification. Mol Biol Rep 37(3):1435–1438CrossRefPubMed
44.
Byers RJ, Hoyland JA, Dixon J, Freemont AJ (2000) Subtractive hybridization genetic takeaways and the search for meaning. Int J Exp Pathol 81(6):391–404CrossRefPubMedPubMedCentral
45.
D’Urso OF, D’Urso PI, Storelli C, Marsigliante S (2010) Solid phase subtractive cloning in differentially expressed genes identification. Mol Biol Rep 37(3):1435–1438CrossRefPubMed
46.
Smith CL, Bouchard J, Surdi G, Nguyen G, Pimpis K, Tolstoi LG (2000) Comparative genomics: differential display and subtractive hybridization. Encycl Anal Chem 6:4893–4901
47.
Seth D, Gorrell MD, McGuinness PH, Leo MA, Lieber CS, McCaughan GW, et al. (2003) SMART amplification maintains representation of relative gene expression: quantitative validation by real time PCR and application to studies of alcoholic liver disease in primates. J Biochem Biophys Methods 55(1):53–66CrossRefPubMed
48.
Hsu F-M, Cheng JC-H, Chang Y-L, Lee J-M, Koong AC, Chuang EY (2015) Circulating mRNA Profiling in Esophageal Squamous Cell Carcinoma Identifies FAM84B As A Biomarker In Predicting Pathological Response to Neoadjuvant Chemoradiation. Sci Report 5
49.
Wang J, Zhang K-Y, Liu S-M, Sen S (2014) Tumor-associated circulating microRNAs as biomarkers of cancer. Molecules 19(2):1912–1938CrossRefPubMed
Metadata
Title
Applying Subtractive Hybridization Technique to Enrich and Amplify Tumor-Specific Transcripts of Esophageal Squamous Cell Carcinoma
Authors
Reihaneh Alsadat Mahmoudian
Mohammad Reza Abbaszadegan
Mehran Gholamin
Publication date
01-04-2017
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2017
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-016-0090-5

Other articles of this Issue 2/2017

Pathology & Oncology Research 2/2017 Go to the issue

Letter to the Editor

WRN, the Werner Syndrome Gene, Exhibits Frameshift Mutations in Gastric and Colorectal Cancers

Original Article

Region Specific Differences of Claudin-5 Expression in Pediatric Intracranial Ependymomas: Potential Prognostic Role in Supratentorial Cases

Original Article

Estrogen Receptors in Regulating Cell Proliferation of Esophageal Squamous Cell Carcinoma: Involvement of Intracellular Ca2+ Signaling

Original Article

Oroxylin a could be a Promising Radiosensitizer for Esophageal Squamous Cell Carcinoma by Inducing G2/M Arrest and Activating Apoptosis

Short Communication

Central Nervous System Involvement at the Time of Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with a Poor Outcome in Patients with Acute Myeloid Leukemia

Original Article

Clinical Roles of Interleukin-6 and STAT3 in Oral Squamous Cell Carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits